Erlotinib Plus Ramucirumab Therapy After Osimertinib Treatment: A Multicenter Observational Study
Abstract
Background Although osimertinib is widely used and is the most recommended drug worldwide for epidermal growth factor receptor (EGFR) -mutated lung cancer, treatment strategies post-osimertinib failure remain unclear. A previous report showed that if administered to patients previously treated with EGFR-tyrosine kinase inhibitors (TKIs), erlotinib or gefitinib plus bevacizumab resulted in an objective response rate (ORR) of 13%, disease control rate (DCR) of 88%, median progression-free survival (PFS) of 4.1 months, and median overall survival (OS) of 13.5 months. However, the efficacy of erlotinib plus ramucirumab therapy in patients previously treated with EGFR-TKIs has not been reported. Methods This retrospective study was designed to exploratorily evaluate the efficacy and safety of erlotinib plus ramucirumab therapy after osimertinib treatment in clinical practice. Forty-three patients with EGFR -mutated lung cancer were enrolled from 14 centers. The primary endpoint was PFS of erlotinib plus ramucirumab therapy. The secondary endpoints were time to treatment failure (TTF), OS, ORR, DCR, and safety of erlotinib plus ramucirumab therapy. Results The median PFS for erlotinib plus ramucirumab therapy was 7.1 months, median TTF 4.8 months, median OS 14.4 months, ORR 31.7%, and DCR 87.8%. In the group in which osimertinib was discontinued because of disease progression, the median PFS was 3.8 months and one-year PFS rate was 19.0%. In the group in which osimertinib was discontinued owing to adverse events, the median PFS was 11.1 months and one-year PFS rate was 48.3%, and treatment was continued without serious adverse events. Conclusions Erlotinib plus ramucirumab therapy may be a promising treatment option for patients with EGFR -mutated lung cancer who received initial treatment with osimertinib, especially in cases in which osimertinib was discontinued owing to adverse events.
Related
- Reduced-dose nanoparticle albumin-bound-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer: a multicenter phase II study
- High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
- Gastrolaryn® Stick Following Proton Pump Inhibitor Treatment in Patients with Gastroesophageal Reflux Disease: A Multicenter Real-World Observational Survey
- Clinical outcomes of angina treatment in coronary microvascular dysfunction: results of a multicenter observational study
- Operative and non-operative treatment of symptomatic adult spinal deformity: a prospective multicenter observational study.
BibTeX
@article{kosukehamaimd2026erlotinib,
title = {{Erlotinib Plus Ramucirumab Therapy After Osimertinib Treatment: A Multicenter Observational Study}},
author = {Kosuke Hamai MD, PhD and Yuka Kato MD, PhD and Kenichi Chikamori MD, PhD and Nobuhisa Ishikawa MD, PhD and Shoichi Kuyama MD, PhD and Kakuhiro Yamaguchi KD, PhD and Kenichiro Kudo MD, PhD and Hiroyasu Shoda MD, PhD and Koji Inoue MD, PhD and Yoshifumi Nishimura MD, PhD and Nagio Takigawa MD, PhD and Shoichiro Yamamoto MD, PhD and Mari Uno MD and Naoki Kinoshita MD, PhD},
journal = {Clinical Medicine Insights: Oncology},
year = {2026},
month = nov,
doi = {10.1177/11795549261504626},
url = {https://doi.org/10.1177/11795549261504626},
note = {CC BY},
}
RIS
TY - JOUR
TI - Erlotinib Plus Ramucirumab Therapy After Osimertinib Treatment: A Multicenter Observational Study
AU - Kosuke Hamai MD, PhD
AU - Yuka Kato MD, PhD
AU - Kenichi Chikamori MD, PhD
AU - Nobuhisa Ishikawa MD, PhD
AU - Shoichi Kuyama MD, PhD
AU - Kakuhiro Yamaguchi KD, PhD
AU - Kenichiro Kudo MD, PhD
AU - Hiroyasu Shoda MD, PhD
AU - Koji Inoue MD, PhD
AU - Yoshifumi Nishimura MD, PhD
AU - Nagio Takigawa MD, PhD
AU - Shoichiro Yamamoto MD, PhD
AU - Mari Uno MD
AU - Naoki Kinoshita MD, PhD
PY - 2026
DA - 2026/11/04
JO - Clinical Medicine Insights: Oncology
DO - 10.1177/11795549261504626
UR - https://doi.org/10.1177/11795549261504626
AB - Background Although osimertinib is widely used and is the most recommended drug worldwide for epidermal growth factor receptor (EGFR) -mutated lung cancer, treatment strategies post-osimertinib failure remain unclear. A previous report showed that if administered to patients previously treated with EGFR-tyrosine kinase inhibitors (TKIs), erlotinib or gefitinib plus bevacizumab resulted in an objective response rate (ORR) of 13%, disease control rate (DCR) of 88%, median progression-free survival (PFS) of 4.1 months, and median overall survival (OS) of 13.5 months. However, the efficacy of erlotinib plus ramucirumab therapy in patients previously treated with EGFR-TKIs has not been reported. Methods This retrospective study was designed to exploratorily evaluate the efficacy and safety of erlotinib plus ramucirumab therapy after osimertinib treatment in clinical practice. Forty-three patients with EGFR -mutated lung cancer were enrolled from 14 centers. The primary endpoint was PFS of erlotinib plus ramucirumab therapy. The secondary endpoints were time to treatment failure (TTF), OS, ORR, DCR, and safety of erlotinib plus ramucirumab therapy. Results The median PFS for erlotinib plus ramucirumab therapy was 7.1 months, median TTF 4.8 months, median OS 14.4 months, ORR 31.7%, and DCR 87.8%. In the group in which osimertinib was discontinued because of disease progression, the median PFS was 3.8 months and one-year PFS rate was 19.0%. In the group in which osimertinib was discontinued owing to adverse events, the median PFS was 11.1 months and one-year PFS rate was 48.3%, and treatment was continued without serious adverse events. Conclusions Erlotinib plus ramucirumab therapy may be a promising treatment option for patients with EGFR -mutated lung cancer who received initial treatment with osimertinib, especially in cases in which osimertinib was discontinued owing to adverse events.
SN - 1179-5549
ER -